| Clinical data | |
|---|---|
| Trade names | HMS, Medrocort, others |
| Other names | NSC-63278; Hydroxymethylprogesterone; Methylhydroxyprogesterone; Hydroxymesterone; 6α-Methyl-11β-hydroxyprogesterone; 6α-Methyl-11β-hydroxypregn-4-ene-3,20-dione |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a606003 |
| Routes of administration | Eye drops |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.018.371 |
| Chemical and physical data | |
| Formula | C22H32O3 |
| Molar mass | 344.495 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Medrysone (INN,USAN; brand namesHMS,Medrocort, others; former developmental codeNSC-63278; also known ashydroxymethylprogesterone,methylhydroxyprogesterone,hydroxymesterone,6α-methyl-11β-hydroxyprogesterone, or6α-methyl-11β-hydroxypregn-4-ene-3,20-dione) is asyntheticglucocorticoid that is or has been used in the treatment ofinflammatoryeye diseases.[1][2][3] It has been discontinued in theUnited States.[4] Although it is very similar instructure toprogesterone,[5] neitherprogestogenic norandrogenic activity has been demonstrated for or attributed to medrysone.[6][7][8]
In 2021, medrysone was one of the 12 compounds identified in sludge samples taken from 12wastewater treatment plants inCalifornia that were associated withestrogenic activity inin vitro.[9]